



(12) **EUROPEAN PATENT APPLICATION**

(88) Date of publication A3:
16.02.2011 Bulletin 2011/07

(51) Int Cl.:
G01N 33/53 (2006.01) **G01N 33/536** (2006.01)
G01N 33/537 (2006.01) **G01N 33/543** (2006.01)
G01N 33/551 (2006.01)

(43) Date of publication A2:
22.12.2010 Bulletin 2010/51

(21) Application number: **10186256.3**

(22) Date of filing: **07.06.2005**

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR
Designated Extension States:
AL BA HR LV MK YU

• **The Trustees of Columbia University**
New York NY 10027 (US)

(30) Priority: **07.06.2004 US 577662 P**
31.03.2005 US 96113

(72) Inventors:
• **Devarajan, Prasad**
Cincinnati, OH 45242 (US)
• **Barasch, Jonathan M**
New York, NY 10023 (US)

(62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC:
05755309.1 / 1 766 395

(74) Representative: **Finnie, Isobel Lara**
Mintz Levin Cohn Ferris Glovsky and Popeo Intellectual Property LLP
Alder Castle
10 Noble Street
London
EC2V 7JX (GB)


(71) Applicants:
• **The Children's Hospital Medical Center**
Cincinnati,
Ohio 45229-3039 (US)

(54) **Method for the early detection of renal disease and injury**

(57) A method and kit for detecting the early onset of renal disease and injury, including renal tubular injury, utilizing NGAL as an early blood serum biomarker. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the blood serum following renal tubule cell injury. NGAL protein expression is detected predominantly in proximal tubule cells,

in a punctate cytoplasmic distribution reminiscent of a secreted protein. The appearance NGAL in the serum is related to the dose and duration of renal ischemia and nephrotoxicity, and is diagnostic of renal tubule cell injury and renal failure. NGAL detection is also a useful marker for monitoring the nephrotoxic side effects of drugs or other therapeutic agents.

Figure 2





EUROPEAN SEARCH REPORT

Application Number
EP 10 18 6256

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
A	OHLSSON S ET AL: "Increased circulating levels of proteinase 3 in patients with anti-neutrophilic cytoplasmic autoantibodies-associated systemic vasculitis in remission.", CLINICAL AND EXPERIMENTAL IMMUNOLOGY MAR 2003, vol. 131, no. 3, March 2003 (2003-03), pages 528-535, XP002467651, ISSN: 0009-9104 * the whole document * * In particular: p. 528, Summary; p. 529-530, Materials and Methods; p. 531, col. 1-2, bridging paragraph; p. 532, Fig. 3; p. 534, col. 1, paragraph 2. *	1-9	INV. G01N33/53 G01N33/536 G01N33/537 G01N33/543 G01N33/551
A	MATTHAEUS T ET AL: "ACUTE ISCHEMIC RENAL FAILURE INDUCES EXPRESSION OF NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN AND MATRIX METALLOPROTEINASE-9 IN DAMAGED TUBULI", KIDNEY AND BLOOD PRESSURE RESEARCH, BASEL, CH, vol. 24, no. 4-6, 29 September 2001 (2001-09-29), page 342, XP009065224, ISSN: 1420-4096 * the whole document *	1-9	TECHNICAL FIELDS SEARCHED (IPC) G01N
E	EP 1 750 500 A (UNIV COLUMBIA [US]; CHILDRENS HOSP MEDICAL CENTER [US]) 14 February 2007 (2007-02-14) * the whole document * * In Particular: p. 28, paragraphs 132-134; p. 36, Example 8; p. 44, Example 17; Figures 11D and 25. *	1-9	
1 The present search report has been drawn up for all claims			
Place of search		Date of completion of the search	Examiner
The Hague		5 January 2011	C.F. Angioni
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

EPO FORM 1503 03.82 (P04C01)



EUROPEAN SEARCH REPORT

Application Number
EP 10 18 6256

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
E	EP 1 616 184 A (CHILDRENS HOSP MEDICAL CENTER [US]; UNIV COLUMBIA [US]) 18 January 2006 (2006-01-18) * the whole document *	1-9	
A	KJELDSSEN L ET AL: "CHARACTERIZATION OF TWO ELISA'S FOR NGAL, A NEWLY DESCRIBED LIPOCALIN IN HUMAN NEUTROPHILS", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, vol. 198, 1 January 1996 (1996-01-01), pages 155-164, XP002061581, ISSN: 0022-1759, DOI: DOI:10.1016/S0022-1759(96)00153-6 * the whole document *	1-9	
A	MISHRA J ET AL: "NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN: A NOVEL EARLY URINARY BIOMARKER FOR CISPLATIN NEPHROTOXICITY", AMERICAN JOURNAL OF NEPHROLOGY, S. KARGER AG, BASEL, CH, vol. 24, 12 May 2004 (2004-05-12), pages 307-315, XP008063174, ISSN: 0250-4095, DOI: DOI:10.1159/000078452 * the whole document *	1-9	
			TECHNICAL FIELDS SEARCHED (IPC)
The present search report has been drawn up for all claims			
Place of search The Hague		Date of completion of the search 5 January 2011	Examiner C.F. Angioni
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

 1
EPO FORM 1503 03.82 (P04C01)



EUROPEAN SEARCH REPORT

Application Number
EP 10 18 6256

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
A	MISHRA J ET AL: "Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, WILLIAMS AND WILKINS, BALTIMORE, MD, US, vol. 14, no. 10, 1 October 2003 (2003-10-01), pages 2534-2543, XP002377943, ISSN: 1046-6673, DOI: DOI:10.1097/01.ASN.0000088027.54400.C6 * the whole document * * In particular: Title; Abstract; Materials and methods section. * -----	1-9	
			TECHNICAL FIELDS SEARCHED (IPC)
The present search report has been drawn up for all claims			
Place of search		Date of completion of the search	Examiner
The Hague		5 January 2011	C.F. Angioni
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

1
EPO FORM 1503 03.82 (P04C01)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 10 18 6256

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

05-01-2011

Patent document cited in search report		Publication date	Patent family member(s)			Publication date
EP 1750500	A	14-02-2007	AU	2005240190	A1	17-11-2005
			CA	2565701	A1	17-11-2005
			JP	2007536260	T	13-12-2007
			US	2005261191	A1	24-11-2005
			US	2010254970	A1	07-10-2010
			WO	2005107793	A2	17-11-2005

EP 1616184	A	18-01-2006	AT	437371	T	15-08-2009
			AU	2004225472	A1	14-10-2004
			BR	PI0408802	A	04-04-2006
			CA	2520658	A1	14-10-2004
			DK	1616184	T3	19-10-2009
			EP	2083270	A1	29-07-2009
			ES	2330005	T3	03-12-2009
			JP	2006521565	T	21-09-2006
			MX	PA05010385	A	08-03-2006
			NZ	543028	A	30-06-2008
			WO	2004088276	A2	14-10-2004

专利名称(译)	早期发现肾脏疾病和损伤的方法		
公开(公告)号	EP2264459A3	公开(公告)日	2011-02-16
申请号	EP2010186256	申请日	2005-06-07
[标]申请(专利权)人(译)	儿童医院医仙 纽约市哥伦比亚大学理事会		
申请(专利权)人(译)	儿童医院医疗中心 哥伦比亚大学的受托人		
当前申请(专利权)人(译)	儿童医院医疗中心 哥伦比亚大学的受托人		
[标]发明人	DEVARAJAN PRASAD BARASCH JONATHAN M		
发明人	DEVARAJAN, PRASAD BARASCH, JONATHAN M		
IPC分类号	G01N33/53 G01N33/536 G01N33/537 G01N33/543 G01N33/551 G01N33/542 G01N33/68		
CPC分类号	G01N33/6893 G01N33/573 G01N2333/82 G01N2800/347 G01N2800/52		
优先权	60/577662 2004-06-07 US PCT/US2005/019951 2005-06-07 WO 11/096113 2005-03-31 US		
其他公开文献	EP2264459A2 EP2264459B1		
外部链接	Espacenet		

摘要(译)

一种利用NGAL作为早期血清生物标志物检测肾病和损伤早期发作的方法和试剂盒，包括肾小管损伤。NGAL是一种小分泌多肽，具有蛋白酶抗性，因此在肾小管细胞损伤后易于在血清中检测到。NGAL蛋白表达主要在近端小管细胞中检测到，呈点状细胞质分布，使人想起分泌的蛋白质。血清中外观NGAL与肾缺血和肾毒性的剂量和持续时间有关，并且是肾小管细胞损伤和肾衰竭的诊断。NGAL检测也是监测药物或其他治疗剂的肾毒性副作用的有用标记物。

Figure 2

